Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2107 articles with Gilead Sciences, Inc.
-
Gilead Sciences, Inc. to Present at the Cowen & Company 27th Annual Health Care Conference on Monday, March 12
3/9/2007
-
Gilead Sciences, Inc. Announces New Appointments Within Executive Team
3/9/2007
-
New AIDS Drugs Offer Hope for Long-Term Patients
3/2/2007
-
Gilead Sciences, Inc. Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
3/2/2007
-
Gilead Sciences, Inc. (Jobs) Study Meets Primary Endpoint of Non-inferiority
2/26/2007
-
The Day In Review: Sanofi-Aventis (France) Loses Lovenox Patent
2/9/2007
-
Gilead Sciences, Inc. To Present At The Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference On Wednesday, February 7
2/5/2007
-
Gilead Sciences, Inc. Announces Fourth Quarter And Full Year 2006 Financial Results
2/1/2007
-
Gilead Sciences, Inc. Announces Senior Management Promotion
1/26/2007
-
Gilead Sciences, Inc. To Release Fourth Quarter And Year End 2006 Financial Results On Wednesday, January 31, 2007
1/25/2007
-
Carla A. Hills Joins Gilead Sciences, Inc.'s Board Of Directors
1/23/2007
-
Gilead Sciences (Foster City, CA) To Present At The 25th Annual JPMorgan Healthcare Conference On Monday, January 8th
1/5/2007
-
Gilead Sciences (Foster City, CA) Submits New Drug Application To U.S. FDA For Ambrisentan For The Treatment Of Pulmonary Arterial Hypertension
12/19/2006
-
96-Week Data From Gilead Sciences (Foster City, CA)'s Study 934 Comparing Viread(R) And Emtriva(R) To Combivir® Both In Combination With Sustiva(R) Published In Journal Of Acquired Immune Deficiency Syndrome
12/15/2006
-
Gilead Sciences (Foster City, CA) Grants Intellectual Property Rights For Tenofovir Topical Gel To The International Partnership For Microbicides And CONRAD
12/12/2006
-
Gilead Sciences (Foster City, CA) Receives Subpoena From U.S. Department Of Justice
12/8/2006
-
Gilead Sciences (Foster City, CA) To Present At The NASDAQ 18th Investor Program On Thursday, December 7
12/4/2006
-
Gilead Sciences (Foster City, CA) To Present At Two Upcoming Investor Conferences
11/27/2006
-
Gilead Sciences (Foster City, CA) Completes Acquisition Of Myogen
11/20/2006
-
Gilead Sciences (Foster City, CA) To Present At The Credit Suisse Healthcare Conference On Friday, November 17th
11/15/2006